内皮素-1前体基因反义寡核苷酸对正常和高血压大鼠血流动力学的影响

我们筛选出针对内皮素－１（ＥＴ－１）前体基因反义硫代寡核苷酸片断（ＥＴＡＳＯＤＮ）,已证明ＥＴＡＳＯＤＮ能显著抑制培养内皮细胞ＥＴ－１的生成,本应用该片断,对下沉和腹主动脉狭窄－高盐摄入型高血压大鼠侧脑室进行注射,记录注射前后血流动力学指标、注射后侧脑室周围组织中ＥＴ－１的含量及分布,ＥＴＡＳＯＤＮ对正常和高血压大鼠的影响,发现高血压大鼠脑干ＥＴ－１含量明显高于正常大鼠;ＥＴＡＳＯＤＮ能降低高血压     

肾动脉内注射内皮素—1对麻醉大鼠肾神经传入放电的影响

本实验旨在观察肾动脉内注射ＥＴ－１对麻醉大鼠血压（ＢＰ）、心率（ＨＲ）和肾神经传入放电（ＡＲＮＡ）的影响,以及ＥＴＡ受体阻断剂ＢＱ－１２３和硝苯吡啶（Ｎｉｆ）对ＥＴ生物学效应的拮抗作用。结果如下：（１）肾动脉注射ＥＴ－１（１μｇ／ｋｇ）后,平均动脉压（ＭＡＰ）先有短暂的降低（由１３．７７±０．１３ｋＰａ降至１０．２±１．１２ｋＰａ）,随后为较显著的持久增高,增值达３．４４±１．６０ｋＰａＰ＜０．００１）,ＨＲ无明显变化,ＡＲＮＡ增加１０８．３３±１６．６７％（Ｐ＜０．００１）。（２）肾动脉内注射ＥＴＡ受体选择性拮抗剂ＢＱ－１２３（１５０μｇ／ｋｇ）,ＥＴ－１的上述效应即被拮抗。与ＥＴ组相比差异非常显著（Ｐ＜０．００１）。（３）肾动脉内注射二氢吡啶敏感性Ｌ－型钙通道阻断剂Ｎｉｆ（０．１ｍｇ／ｋｇ）,也可明显抑制ＥＴ－１的上述效应,与ＥＴ组相比差异十分显著（Ｐ＜０．００１）。以上结果表明：肾动脉内注射ＥＴ－１引起的麻醉大鼠ＭＡＰ增高和ＡＲＮＡ积分增加的作用,可能是由ＥＴＡ受体介导的,其作用的细胞机制可能在于胞内钙超载     

膀胱癌中内皮素作用的研究

应用Ｎｏｒｔｈｅｒｎｂｌｏｔ杂交技术及放射免疫方法对人膀胱移行细胞癌组织中内皮素－１ｍＲＮＡ及内皮素活性分子的表达水平进行检测,研究了佛波酯对人膀胱移行细胞癌ＢＩＵ－８７细胞中内皮素活性分子表达水平的调节作用,并探讨了内皮素抗血清及内皮素Ａ型受体竞争性拮抗剂ＢＱ_（１２３）对ＢＩＵ－８７细胞ＤＮＡ合成的影响。结果表明,人膀胱移行细胞癌组织中内皮素－ｌｍＲＮＡ及内皮素活性分子的表达水平明显高于相应的癌旁组织,佛波酯可促进ＢＩＵ－８７细胞合成和分泌内皮素,内皮素抗血清及ＢＱ_（１２３）可抑制ＢＩＵ－８７细胞合成ＤＮＡ。提示内皮素在膀胱癌发展及ＢＩＵ－８７细胞恶性增殖中可能起重要作用。     

内皮素—1对缺氧肺脉平滑肌细胞的增殖作用

内皮素（ＥＴ）是至今所发现的最强的内源性血管收缩肽,近年来发现ＥＴ－１能促进血管平滑肌细胞增殖。本研究表明ＥＴ－１对缺氧培养的肺动脉平滑肌细胞（ＰＡＳＭＣ）有剂量依赖的增殖作用,缺氧可ＰＡＳＭＣ的ＤＮＡ合成且增加ＥＴ－１的丝裂原作用。ＥＴ－１的丝裂原作用主要由其Ａ型受体（ＥＴＲＡ）所介导,ＥＴＲＡ的特异拮抗剂ＢＱ１２３可显著抑制缺氧以及缺氧与ＥＴ－１协同所产生的增殖作用,而且发现ＥＴＲＡ在缺氧培养     

新生鼠心室成纤维细胞条件培养液增加心肌细胞搏动频 …

目的和方法：利用细胞培养和ＴＲ－ＰＣＲ技术研究新生大鼠心脏成纤维细胞增加心肌细胞搏动频率的作用。结果：成纤维细胞条件培养液在４８ｈ内能明显增加心肌细胞的搏动频率,并具有时间依赖性和剂量依赖性,内皮素－１（ＥＴ－１）ＥＴＡ受体拮抗剂ＢＱ１２３能部分阴断成纤维细胞条件培养液增加心肌细胞搏动频率作用,而血管紧张素ⅡＡＴ１受体拮抗剂ＣＶ１１９７４和α－肾上腺素受体拮抗剂Ｒｅｇｉｔｉｎ却无此效果：ＲＴ－ＰＣ     

内皮素对培养心肌细胞内游离钙浓度的作用

实验用培养新生ＳＤ大鼠心室肌细胞,以Ｆｕｒａ－２／ＡＭ荧光指示剂负载检测收肌细胞内游离钙浓度（「Ｃａ＾２＋」）的变化,探讨内皮素－１（ＥＴ－１）对「Ｃａ＾２＋」ｉ的作用及其机制。结果显示：ＥＴ－１引起心肌细胞「Ｃａ＾２＋」ｉ升高有两个时相,瞬时相持续相。ＥＴ－１诱导的瞬时相「Ｃａ＾２＋」ｉ升高呈浓度依赖性,预先用ＥＴＡ特异性受阻断剂ＢＱ１２３处理,可阻断ＥＴ－１引起的「Ｃａ＾２＋」ｉ升高,揭示上述     

内皮素－1对缺氧肺动脉平滑肌细胞的增殖作用

内皮素（ＥＴ）是至今所发现的最强的内源性血管收缩肽,近年来发现ＥＴ－１能促进血管平滑肌细胞增殖。本研究表明ＥＴ－１对缺氧培养的肺动脉平滑肌细胞（ＰＡＳＭＣ）有剂量依赖的增殖作用,缺氧可促进ＰＡＳＭＣ的ＤＮＡ合成且增加ＥＴ－１的丝裂原作用。ＥＴ－１的丝裂原作用主要由其Ａ型受体（ＥＴＲ＿Ａ）所介导,ＥＴＲ＿Ａ的特异拮抗剂ＢＱ１２３可显著抑制缺氧以及缺氧与ＥＴ－１协同所产生的增殖作用,而且发现ＥＴＲ＿Ａ在缺氧培养的ＰＡＳＭＣ中的表达显著高于常氧对照组ＰＡＳＭＣ。本研究表明ＥＴ－１参与了缺氧性肺动脉结构重组,而缺氧可增强ＰＡＳＭＣ对ＥＴ－１的增殖反应性。     

膀胱癌中内皮素作用的研究

应用Ｎｏｒｔｈｅｒｎ ｂｌｏｔ杂交技术及放射免疫方法对人膀胱移行细胞癌组织中内皮素－１ｍＲＮＡ及内皮素活性分子的表达水平进行检测,研究了佛波酯对人膀胱移行细胞癌ＢＩＵ－８７细胞中内皮素活性分子表达水平的调节作用,并探讨了内皮素抗血清及内皮素Ａ型受体竞争性拮抗剂ＢＱ１２３对ＢＩＵ－８７细胞ＤＮＡ合成的影响。结果表明,人膀胱移行细胞癌组织中内皮素－１ｍＲＮＡ及内皮素活性分子的表达水平明显高于相应的癌旁     

内皮素对豚鼠乳头肌电生理和收缩活动的影响

应用细胞内微电极和肌张力记录技术,观察了ＥＴ－１对豚鼠乳头肌细胞电生理和机械收缩活动的影响。结果表明：ＥＴ－１浓度依赖地明显延长ＰＰＤ和ＡＰＤ９０,增加收肌收缩张力;钾通道阻断剂ＴＥＡ不影响ＥＴ－１的生物效应;而Ｌ型钙通道阻断剂硝苯吡啶、ＥＴＡ受体选择性拮抗剂ＢＱ－１２３和ＡＰⅢ以浓度依赖的方式阻断ＥＴ－１的上述效应,提示ＥＴ－１对乳头肌的电生理和正性肌力效应是由ＥＴＡ受体亚型介导的,与胞浆内Ｃａ     

内皮素-1对培养新生大鼠心肌细胞原癌基因c-fos表达的诱导

本实验用无血清的培养新生大鼠心肌细胞,探讨内皮素１（ＥＴ１）对原癌基因ｃｆｏｓ表达的作用。结果显示：ＥＴ１可显著诱导ｃｆｏｓ的表达,其表达的高峰在３０ｍｉｎ,２ｈ恢复到正常水平,并呈剂量依赖性反应和被ＥＴＡ的特异性受体拮抗剂ＢＱ１２３所阻断;蛋白激酶Ｃ（ＰＫＣ）激动剂ＰＭＡ可诱导ｃｆｏｓ表达,而ＰＫＣ抑制剂Ｓｔａｕｒｏｓｐｏｒｉｎｅ则可阻断ＥＴ１诱导的ｃｆｏｓ表达;钙通道阻断剂硝苯吡啶预处理心肌细胞对ＥＴ１诱导的心肌细胞的ｃｆｏｓ表达无明显的作用。这些结果提示,ＥＴ１诱导ｃｆｏｓ表达是通过ＥＴＡ受体介导的,ＰＫＣ在此过程中起重要作用。     

Potentiation of morphine analgesia by BQ123, an endothelin antagonist

Several neurotransmitter mechanisms have been proposed to play a role in the actions of morphine. The present study is the first to provide evidence that central endothelin (ET) mechanisms are involved in the modulation of pharmacological actions of morphine. The effect of intracerebroventricular (i.c.v.) administration of endothelin-A (ET(A)) antagonist, BQ123, on morphine-induced analgesia, hyperthermia, and catalepsy was determined in the rat. Morphine produced a significant increase in tail-flick latency as compared to control group. Pretreatment with BQ123 significantly potentiated the effect and duration of morphine (2 and 8 mg/kg, s.c.)-induced analgesia as compared to vehicle-pretreated control rats. The hyperthermic effect of morphine was not only significantly greater in BQ123-pretreated rats but also lasted for more than 6 h. ET antagonist, BQ123, did not affect the pharmacological effect of morphine on cataleptic behavior. These studies demonstrate that BQ123, a specific ET(A) receptor antagonist, significantly potentiated morphine-induced analgesia and hyperthermia in rats without affecting morphine-induced cataleptic behavior. [(3)H]-Naloxone binding was carried out to determine the possibility of BQ123 acting on opiate receptors. It was found that morphine could displace [(3)H]-naloxone but BQ123 did not affect [(3)H]-naloxone binding even at 1,000 nM concentration. Therefore, it can be concluded that BQ123 does not act on opioid receptors. This is the first report suggesting that an ET(A) antagonist, BQ123, significantly potentiates the analgesic effect of morphine, possibly through a nonopioid mechanism.     

Endothelin receptor antagonists restore morphine analgesia in morphine tolerant rats

Several neurotransmitter mechanisms have been proposed to play a role in the development of morphine tolerance. The present study provides evidence for the first time that endothelin (ET) antagonists can restore morphine analgesia in morphine tolerant rats. Tolerance to morphine was induced by subcutaneous implantation of six morphine pellets during a 7-day period. The degree of tolerance to morphine was measured by determining analgesic response (tail-flick latency) and hyperthermic response to morphine sulfate (8 mg/kg, subcutaneously (s.c.)) in placebo and morphine pellet implanted rats. The maximal tail-flick latency in morphine pellet-vehicle treated rats (7.54 s) was significantly lower (P<0.05) when compared to placebo pellet-vehicle treated rats (10s), indicating that tolerance developed to the analgesic effect of morphine. In separate sets of experiments, ET antagonists, BQ123 (10 microg, intracerebroventricularly (i.c.v.)) and BMS182874 (50 microg, i.c.v.) were administered in placebo and morphine tolerant rats. BQ123 was injected twice daily for 7 days and once on day 8. BMS182874 was administered only on day 8. Morphine (8 mg/kg, s.c.) was administered 30min after BQ123 or BMS182874 administration. It was found that both BQ123 and BMS182874 potentiated morphine analgesia in placebo and morphine tolerant rats. BQ123 potentiated tail-flick latency by 30.0% in placebo tolerant rats and 94.5% in morphine tolerant rats compared to respective controls. BMS182874 potentiated tail-flick latency by 30.2% in placebo tolerant rats and 66.7% in morphine tolerant rats. Morphine-induced hyperthermic effect was also potentiated by BQ123 and BMS182874. The duration of analgesic action was also prolonged by BQ123 and BMS182874. The effect of BMS182874 was less as compared to BQ123. BQ123 and BMS182874 are selective ET(A) receptor antagonists. Therefore, it is concluded that ET(A) receptor antagonists restore morphine analgesia in morphine tolerant rats.     

Role of Endogenous ET‐1 in the Regulation of Myocardial Blood Flow in Lean and Obese Humans

Endothelin is an important determinant of peripheral vascular tone, and increased endogenous endothelin activity contributes to peripheral vascular dysfunction in human obesity. The contributions of endothelin to the regulation of coronary vascular tone in health in humans have not been well studied. We hypothesized that the contribution of endothelin to the regulation of myocardial perfusion would be augmented in human obesity. Using [NH₃]ammonia positron emission tomography (PET), we measured myocardial perfusion under resting and adenosine‐stimulated conditions on two separate days, with and without concurrent exposure to BQ123, an antagonist of type A endothelin receptors (1 µmol/min IV beginning 90 min before measurement). We studied 10 lean and 9 obese subjects without hypertension, hyperlipidemia, or diabetes mellitus. We observed a BQ123‐induced increase in resting myocardial perfusion of ～40%, not different between lean and obese subjects (BQ123‐induced increase in flow: lean 0.12 ± 0.20, obese 0.32 ± 0.51 ml/g/min, P = 0.02 BQ123 effect, P = 0.27 comparing response across groups). Although basal flow rates varied by region of the myocardium, the BQ123 effect was seen in all regions. BMI and cholesterol were significantly related to BQ123‐induced increases in basal tone in multivariable analysis. There was no baseline difference in the adenosine‐stimulated increase in blood flow between lean and obese subjects, and BQ123 failed to augment these responses in either group. These observations suggest that endothelin is an important contributor to the regulation of myocardial perfusion under resting conditions in healthy lean and obese humans, with increased contributions in proportion to increasing obesity.     

Effects of endothelin-1 1-31 on cell viabililty and [Ca2+]i in cultured neonatal rat cardiomyocytes

We previously found that Endothelin-1(1-31) (ET-1(1-31)) exhibited a pro-arrhythmogenic effect in isolated rat hearts. In this study, we further investigated the effects of ET-1(1-31) on a cell viability and observed [Ca(2+)](i) in cultured cardiomyocytes. Cultured neonatal rat cardiomyocytes were treated with 0.1, 1, and 10 nM ET-1(1-31) for 24h in the presence or absence of ET(A) receptor antagonist (BQ(123)) or phosphoramidon, a NEP/ECE inhibitor. Cell injury was evaluated by supernatant lactate dehydrogenase (LDH) assay, superoxide dismutase (SOD) activity, and malondialdehyde (MDA) content. Cell viability was assessed by MTT assay. [Ca(2+)](i) was measured with Fluo-3/AM under a laser confocal microscope. 1) ET-1(1-31) dose-dependently increased LDH release and decreased cell viability. 2) LDH and MDA levels were significantly elevated and SOD activity decreased after administration of 1 nM ET-1(1-31) for 24h, and these changes were markedly attenuated by 1 uM BQ(123). 3) Exposure to 10 nM ET 1(1-31) caused a continuous increase in [Ca(2+)](i) to cultured beating cardiomyocytes and termination of [Ca(2+)](i) transient within 6 min, and this change was reversed by 1 uM BQ(123) and attenuated by 0.5 mM phosphoramidon. These results suggest that ET-1(1-31) could cause cell injury, and that the effect of ET-1(1-31) on [Ca(2+)](i) transients is mainly mediated by ET(A) receptor and partially attributed to the conversion of ET-1(1-31) to ET-1(1-21).     

内皮素-1对大鼠血管平滑肌细胞产生MCP-1的影响及其机制

目的：观察内皮素-1（ET-1）对大鼠血管平滑肌细胞（VSMCs）产生单核细胞趋化蛋白-1（MCP-1）的影响及其机制。方法：培养大鼠血管平滑肌细胞（VSMCs）。细胞分为2组：ET-1刺激组：以不同浓度ET-1刺激VSMCs不同时间;阻断剂干预组：VSMCs分别与不同阻断剂[ET_AR、ET_BR阻断剂BQ123、BQ788,抗氧化剂N-乙酰半胱氨酸（NAC）,ERK、p38MAPK、JNK及NF-κB抑制剂PD98059、SB203580、SP600125及PDTC]预先孵育30 min,再加入ET-1刺激24 h。在预定时间,以酶联免疫吸附（ELISA）法、逆转录聚合酶链反应（RT-PCR）法分别测定不同因素下VSMCs MCP-1蛋白质及mRNA表达量。VSMCs分别与不同阻断剂（BQ123、BQ788、NAC、PD98059、SB203580及SP600125预先孵育20 min,再加入ET-1刺激5 min,免疫印迹（WB）法测定VSMCs胞浆中细胞外调节蛋白激酶（ERK）、p38丝裂原活化蛋白激酶（p38MAPK）、c-Jun氨基末端激酶（JNK）及其各自磷酸化蛋白质的水平。各项检测均重复3次。结果：ET-1能刺激VSMCs MCP-1蛋白质及mRNA表达,其表达量随ET-1浓度及刺激时间的增加呈升高趋势（P<0.05,P<0.01）;BQ123、NAC、PD98059、SB203580及PDTC能显著抑制ET-1诱导的大鼠VSMCs MCP-1蛋白质及mRNA表达（P<0.01）,而BQ788及SP600125对此作用无明显影响。BQ123、NAC与PD98059或SB203580能分别抑制ET-1刺激后VSMCs胞浆内ERK及p38MAPK的磷酸化（P<0.05,P<0.01）,而ET-1对JNK的磷酸化无明显激活作用。结论：ET-1通过ET_AR、ROS、ERK、p38MAPK及NF-κB诱导大鼠VSMCs产生MCP-1。     

大鼠脑室内注射氨甲酰胆碱对肾钠,钾,水排出的影响

在麻醉大鼠侧脑室注射胆碱能激动剂氨甲酰胆碱（ＣＢＣ）引起显著的促钠排泄、促钾排泄和利尿反应（Ｐ＜０．０５）,其中促钠排泄反应与剂量之间呈量效关系（ｒ＝０．９９９７,Ｐ＜０．０５）。由脑室注射ＣＢＣ（２．７４×１０－３μｍｏｌ）引起的上述反应可以被胆碱能Ｍ受体阻断剂阿托品或Ｎ受体阻断剂六甲双胺预处理完全阻断（Ｐ＜０．０５）。同样,ＣＢＣ的肾脏效应也可被肾上腺素能α受体阻断剂酚妥拉明预处理所部分阻断（Ｐ＜０．０５）。上述结果表明脑室注射ＣＢＣ引起的促钠排泄、促钾排泄和利尿反应是刺激了脑胆碱能Ｍ或Ｎ受体,有部分效应可能继发刺激去甲肾上腺素能α受体。     

Endothelin, PAF and thromboxane A2 in allergic pulmonary hyperreactivity in mice

The role of endothelin, PAF and thromboxane A2 in airway hyperreactivity (AHR) to carbachol induced by ovalbumin sensitization and challenge in Balb/c mice was investigated. Ovalbumin sensitization and challenge induced significant AHR to carbachol in actively sensitized and challenged mice. Treatment of these mice with the PAF antagonist CV-3988 (10 microg kg(-1), i.v.) completely abolished OVA-induced AHR to carbachol. Treatment of sensitized mice with the TxA2 antagonist L-654,664 (1 mg kg(-1), i.v.) partially blocked the induction of AHR in OVA-challenged mice. The intranasal administration of 50 pmol of the ET(A) receptor antagonist BQ-123 had no effect on the PIP but produced a significant reduction at the dose of 100 pmol. The intravenous administration of BQ-123 (100 pmol) reduced the PIP only at the highest doses of carbachol. The ET(B) receptor antagonist BQ-788 administered either via the intranasal or intravenous route had no effect on the PIP at the dose of 100 pmol. Na?ve mice treated with either U-44069 (25 or 100 microg kg(-1), i.v.), endothelin-1 (100 pmol, intranasally) or the ET(B) receptor agonist IRL-1620 (100 pmol, intranasally) showed a marked increase in airway reactivity to carbachol. These results suggest an important role for endothelin, PAF and thromboxane A2 in AHR in mice actively sensitized and challenged with ovalbumin.     

Effect of endothelin-1(1-31) on intracellular free calcium in cultured human mesangial cells

We found that human chymase selectively produces 31-amino-acid length endothelins (1-31) (ETs(1-31)). We investigated the effect of synthetic ET-1(1-31) on intracellular free Ca2+ concentration ([Ca2+]i) in cultured human mesangial cells. ET-1(1-31) increased [Ca2+]i in a concentration-dependent manner to a similar extent as ET-1. The ET-1 (1-31)-induced [Ca2+]i increase was not influenced by removal of extracellular Ca2+ but was inhibited by thapsigargin. ET-1(1-31)-induced [Ca2+]i increase was not affected by phosphoramidon. It was inhibited by BQ123, but not by BQ788. These results suggest that ET-1(1-31) by itself exhibits bioactive properties probably through endothelin ET(A) or ET(A)-like receptors. Since human chymase has been reported to exist in the kidney, ET-1(1-31) may be a candidate substance for mesangium-relevant diseases.     

Cardiovascular effects of cadmium on intravenous and intracerebroventricular administration in rats

Cardiovascular responses to the intravenous (i.v.) and the intracerebroventricular (i.c.v.) administration of cadmium acetate were evaluated in rats anaesthetized with urethane. Cadmium acetate (1 mg/kg i.v.) caused an initial fall followed by a persistent rise in blood pressure. Cadmium acetate (1 microgram i.c.v.) produced a more marked hypertensive effect. In the spinal-transected rat, the effect of intravenous cadmium was reduced but the effect of intraventricularly administered cadmium was completely abolished. It is, therefore, suggested that both central and peripheral mechanisms are involved in the pressor response to cadmium exposure.     

Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49

Tumor-associated glycoprotein-72 (TAG-72) is overexpressed in a high percentage of epithelial cancers and has proven useful as a target for imaging and targeted radiotherapy. Our goal was to express a recombinant Fab (rFab) of the TAG-72 monoclonal antibody CC49 in Pichia pastoris and directly compare its tumor and normal tissue uptake and imaging properties with enzymatically generated Fab (eFab). In this study, the genes coding for CC49 Fab were cloned from hybridoma cells and expressed in P. pastoris. Fab was purified to homogeneity and its immunoreactivity toward bovine submaxillary mucin (TAG-72) confirmed by ELISA. The tumor and normal tissue localization of (123)I-CC49 rFab and eFab were compared in athymic mice bearing s.c. LS174T colon cancer or TAG-72-negative A375 melanoma xenografts. Results showed that pure and immunoreactive rFab of CC49 was produced and labeled with (123)I. At 24 h post i.v. injection (p.i.), tumor uptake for (123)I-rFab in LS174T xenografts was 6.0% ID/g which was 18-fold higher than in A375 tumors. Tumor-to-normal tissue ratios increased between 2 and 24 h and exceeded 5:1 at 24 h p.i. of (123)I-rFab. (123)I-rFab exhibited significantly lower liver uptake at 12 h p.i. and lower kidney uptake at 2 h p.i. than (123)I-eFab. LS174T tumors were imaged as early as 2 h after administration of (123)I-rFab. We conclude that CC49 rFab can be produced in a P. pastoris host system and accumulated at comparable levels as eFab in LS174T colon cancer xenografts in mice. The lower liver uptake of (123)I-rFab as compared with eFab suggests that it may be more useful for imaging liver lesions. No major effect, except for kidneys and liver, was observed on tumor and normal tissue uptake due to introduction of hexahistidine and FLAG affinity tags or peptide linkers in the scaffold of rFab.